112 related articles for article (PubMed ID: 1743628)
1. VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases.
Dupriez B; Morel P; Fenaux P; Colcher-Plantier I; Facon T; Bauters F
Hematol Oncol; 1991; 9(4-5):259-66. PubMed ID: 1743628
[TBL] [Abstract][Full Text] [Related]
2. The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Plantier-Colcher I; Dupriez B; Simon M; Detourmignies L; Jouet JP; Fenaux P; Bauters F; Morel P
Leukemia; 1999 Feb; 13(2):282-8. PubMed ID: 10025903
[TBL] [Abstract][Full Text] [Related]
3. Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma Groups.
Child JA; Simmons AV; Barnard DL; Parapia L; Morgan M; Grace RJ; Fletcher J; Parker D; Norfolk DR; Stone J
Hematol Oncol; 1991; 9(4-5):235-44. PubMed ID: 1743626
[TBL] [Abstract][Full Text] [Related]
4. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.
Herbrecht R; Ortiz S; Damonte JC; Liu KL; Maloisel F; Dufour P; Bergerat JP; Oberling F
Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
7. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Enblad G; Hagberg H; Glimelius B
Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
10. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
14. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
15. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Enblad G; Glimelius B; Hagberg H; Lindemalm C
Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
[TBL] [Abstract][Full Text] [Related]
16. Experience with salvage regimens at M.D. Anderson Hospital.
Cabanillas F
Ann Oncol; 1991 Jan; 2 Suppl 1():31-2. PubMed ID: 1904269
[TBL] [Abstract][Full Text] [Related]
17. [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Li HH; Wu XX; Wang QS; Zhao Y; Bo J; Wang SH; DA WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):298-300. PubMed ID: 16638201
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
